Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in...

Full description

Bibliographic Details
Main Authors:	Kissling, E, Hooiveld, M, Sandonis Martín, V, Martínez-Baz, I, William, N, Vilcu, A-M, Mazagatos, C, Domegan, L, de Lusignan, S, Meijer, A, Machado, A, Brytting, M, Casado, I, Murray, J-LK, Belhillil, S, Larrauri, A, O'Donnell, J, Tsang, R, de Lange, M, Rodrigues, AP, Riess, M, Castilla, J, Hamilton, M, Falchi, A, Pozo, F, Dunford, L, Cogdale, J, Jansen, T, Guiomar, R, Enkirch, T, Burgui, C, Sigerson, D, Blanchon, T, Martínez Ochoa, EM, Connell, J, Ellis, J, van Gageldonk-Lafeber, R, Kislaya, I, Rose, AM, Valenciano, M
Other Authors:	I-MOVE-COVID-19 primary care study team
Format:	Journal article
Language:	English
Published:	European Centre for Disease Prevention and Control 2021

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Similar Items